LXPA 1988
Alternative Names: LXP-107; LXPA-1988Latest Information Update: 09 Feb 2026
At a glance
- Originator LAUNXP Biomedical
- Class Antineoplastics
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia